Clinical trials
Advanced Solid Tumor clinical trials
Below are recruiting advanced solid tumor clinical trials, each written for real people, not researchers. We’re tracking 1,397 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05768932RecruitingPhase 1
Study drug for advanced cancers or relapsed AML
This Phase 1 trial tests BAL0891, a new study treatment, in people with advanced solid tumors that have run out of treatment options, or in relapsed/refractory acute myeloid leukemia (AML). The goal is to find a safe dose and see how well it may work in these hard-to-treat cancers.
New Haven, ConnecticutAges 18 years+ - NCT05784688RecruitingPhase 1/Phase 2
TU2218 with Keytruda for advanced solid tumors
This trial studies TU2218 taken with Keytruda (pembrolizumab) in adults with advanced solid cancers that have limited treatment options. The goal is to see if the combination can shrink tumors and is safe enough to keep using.
San Antonio, TexasAges 18 years+ - NCT05785039RecruitingPhase 2
Study drug for advanced bladder and other solid cancers
This Phase 2 trial tests BL-B01D1 to treat people with advanced or metastatic urothelial (urinary tract) cancer and other solid tumors. You may be eligible if standard treatments are no longer working or are not available, and you can meet safety and cancer-measurement requirements.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05785741RecruitingPhase 1/Phase 2
DB-1310 for advanced solid tumors after standard treatment fails
This early-phase study tests DB-1310 in people with advanced or metastatic solid cancers that have come back or worsened after standard treatments. It aims to find the safest dose and whether it can help shrink tumors or slow cancer growth.
Sacramento, CaliforniaAges 18 years+ - NCT05824975RecruitingPhase 1/Phase 2
Test drug GI-102 alone or with cancer medicines
This Phase 1/2 study tests whether GI-102 is safe and can help shrink advanced solid tumors. It also looks at GI-102 used with standard cancer treatments like pembrolizumab or trastuzumab deruxtecan (T-DXd).
Scottsdale, ArizonaAges 18 years+ - NCT05842785RecruitingPhase 1/Phase 2
Study drug for hard-to-treat advanced solid cancers or lymphomas
This early-phase study tests TSN222 in people with advanced, hard-to-treat solid tumors or lymphomas. It aims to see whether the drug can shrink tumors or improve outcomes, including in specific cancer types like head and neck cancer and melanoma.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05856981RecruitingPhase 1
Testing ADU-1805 for advanced solid tumors safety
This early study tests whether ADU-1805 is safe in people with advanced solid tumors and checks how the body processes the drug. Depending on your cancer type, it may also be looking specifically at certain cancers that have not yet received PD-(L)1 immunotherapy.
Detroit, MichiganAges 18 years+ - NCT05867251RecruitingPhase 1/Phase 2
AVZO-021 for advanced breast and ovarian cancers
This early-stage study tests AVZO-021, a new anti-cancer medicine, in people with advanced solid tumors like specific types of breast and ovarian (or related) cancers. It’s meant to find the safest dose and look for signs the medicine can shrink tumors, especially in cancers with certain gene changes.
New Haven, ConnecticutAges 18 years+ - NCT05877430RecruitingPhase 1/Phase 2
Testing an anti-cancer drug plus pembrolizumab for advanced cancers
This Phase 1/2 study tests the safety and early signs of benefit from CJRB-101 when combined with pembrolizumab (Keytruda) in people with advanced or metastatic lung, head and neck, or melanoma cancer. It may help some participants, but the main goal is to see how safe the combination is and whether it can control cancer.
Irvine, CaliforniaAges 18 years+ - NCT05880043RecruitingPhase 1/Phase 2
IV NK cell treatment for advanced cancers that returned
This Phase 1/2 study tests an intravenous (IV) immune-cell therapy made from donors (allogeneic NK cells) to treat advanced solid tumors, relapsed/refractory non-Hodgkin lymphoma, or multiple myeloma. It may help by targeting cancer cells more directly, but early-phase trials mainly focus on safety and finding the right dosing.
SeoulAges 19 years+ - NCT05888532RecruitingPhase 1/Phase 2
Testing a copper-based scan and treatment in advanced cancers
This Phase 1/2 trial studies a copper-labeled medicine called 64Cu-GRIP B in people with advanced, metastatic cancers. It may help doctors see where cancer is and how well the drug works, especially alongside immune checkpoint therapy for some cancer types.
San Francisco, CaliforniaAges 18 years+ - NCT05892718RecruitingPhase 1
Testing an immune drug for hard-to-treat cancers
This early-phase study tests HCB101, an immune-targeting drug, to see if it is safe and can shrink certain solid tumors or non-Hodgkin lymphoma. It may help people whose cancer has returned or stopped responding to standard treatments.
Port Saint Lucie, FloridaAges 18 years+ - NCT05898399RecruitingPhase 1/Phase 2
Testing ART6043 for advanced cancers with DNA repair defects
This early-phase study tests ART6043 in people with advanced or metastatic solid tumors, and in some parts with breast cancer plus specific gene changes. The goal is to see how well it works and whether it is safe, sometimes combined with olaparib.
Grand Rapids, MichiganAges 18 years+ - NCT05902988RecruitingPhase 1/Phase 2
Study of VLS-1488 for advanced cancers
This early-phase study tests VLS-1488, a new cancer medicine, in people with advanced cancers that have limited treatment options. It may help by finding a safe dose and whether it can shrink or control tumors.
Los Angeles, CaliforniaAges 18 years+ - NCT05914116RecruitingPhase 1/Phase 2
Early study of DB-1311 with BNT324 for advanced solid tumors
This Phase 1/2a study tests a combination treatment (DB-1311 with BNT324) in people with advanced or metastatic solid cancers that have grown despite standard treatments. It aims to find a safe dose and look for signs the treatment can shrink tumors or slow growth.
Tucson, ArizonaAges 18 years+ - NCT05932862RecruitingPhase 1
Test drug XL309 for advanced tumors with HRR gene changes
This early-phase study tests XL309 (and sometimes a mix of XL309 with another treatment) in people whose advanced solid tumors have specific DNA-repair gene changes, such as BRCA1/2 or other HRR-related changes. It aims to see how well the drug works and what dose is safest for these cancers.
Fountain Valley, CaliforniaAges 18 years+ - NCT05941507RecruitingPhase 1/Phase 2
TROP2 antibody drug with anti–PD-1 for advanced solid tumors
This early-phase study tests an antibody-drug (an ADC) that targets TROP2, given by itself and together with an anti–PD-1 medicine. It’s for people with advanced solid cancers that have not responded to standard treatments, aiming to shrink tumors and improve control of the disease.
Los Angeles, CaliforniaAges 18 years+ - NCT05947487RecruitingPhase 1/Phase 2
CAR-T treatment for CD70-positive advanced solid tumors
This Phase 1/2 trial tests a lab-made immune therapy (CAR-T) designed to attack cancers that have a protein called CD70. It may help people whose solid tumor has not responded to standard treatment, but it also requires specific lab confirmation and careful health screening.
Beijing, Iotherapeutic Department of Chinsese PLA Gereral HospitalAges 18–75 - NCT05954312RecruitingPhase 1
Study of an experimental drug for advanced solid tumors
This Phase 1 trial tests VVD-130037, a new experimental medicine, to see if it is safe and tolerable in people with advanced (metastatic or unresectable) solid cancers. If you have already tried standard treatments and your body can handle study medication, you may be eligible—especially for certain lung, head and neck, or esophageal cancer types with specific genetic changes.
Jacksonville, FloridaAges 18 years+ - NCT05965856RecruitingPhase 2
Testing two antibody medicines for advanced bladder and other cancers
This Phase 2 trial studies whether the study medicines SI-B003 alone or together with BL-B01D1 plus SI-B003 can shrink or control advanced cancers that have not responded to standard treatment (or where standard treatment isn’t possible). It also looks at safety and how well the treatment works in people whose cancer can be measured on scans.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05969860RecruitingPhase 2
Home cancer treatment vs clinic treatment for advanced cancer
This Phase 2 trial compares giving certain standard cancer infusions at home versus in a clinic. It may help people avoid clinic visits while still receiving the same cancer treatment safely.
Jacksonville, FloridaAges 18 years+ - NCT05983523RecruitingPhase 1
Study of PEP07 for advanced solid tumors
This study tests a new pill called PEP07 for people with advanced or metastatic solid tumors that have not responded to or cannot tolerate standard treatments. The goal is to see if PEP07 can help shrink or control the cancer.
TaichungAges 20 years+ - NCT06005740RecruitingPhase 1
Study of TORL-4-500 for advanced solid tumors
This trial tests a new investigational drug, TORL-4-500, for people with advanced solid tumors that have not responded to other treatments. It aims to find a safe dose and see if the drug can help shrink or control the cancer.
Phoenix, ArizonaAges 18 years+ - NCT06022029RecruitingPhase 1
Study of injected ONM-501 alone or with cemiplimab for advanced cancers
This trial tests an injected study drug (ONM-501) alone or with another drug (cemiplimab) for people with advanced solid tumors or lymphomas that haven't responded to other treatments. It aims to find a safe dose and see if the combination helps shrink or control the cancer.
Los Angeles, CaliforniaAges 18 years+
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced solid tumor?
- Yes. Clin2 currently lists 1,397 recruiting advanced solid tumor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced solid tumor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced solid tumor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.